The price-to-earnings ratio for Thermo Fisher Scientific Inc (NYSE: TMO) is above average at 23.47x, Company’s 36-month beta value is 0.78.Analysts have differing opinions on the stock, with 18 analysts rating it as a “buy,” 7 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for TMO is 376.79M, and currently, short sellers hold a 1.21% ratio of that floaft. The average trading volume of TMO on June 04, 2025 was 2.51M shares.
TMO) stock’s latest price update
Thermo Fisher Scientific Inc (NYSE: TMO)’s stock price has plunge by 0.87relation to previous closing price of 396.47. Nevertheless, the company has seen a -0.90% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-06-03 that Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.
TMO’s Market Performance
Thermo Fisher Scientific Inc (TMO) has experienced a -0.90% fall in stock performance for the past week, with a -5.58% drop in the past month, and a -22.58% drop in the past quarter. The volatility ratio for the week is 1.07%, and the volatility levels for the past 30 days are at 2.59% for TMO. The simple moving average for the past 20 days is -1.76% for TMO’s stock, with a -24.46% simple moving average for the past 200 days.
Analysts’ Opinion of TMO
Many brokerage firms have already submitted their reports for TMO stocks, with Bernstein repeating the rating for TMO by listing it as a “Outperform.” The predicted price for TMO in the upcoming period, according to Bernstein is $630 based on the research report published on January 10, 2025 of the current year 2025.
TMO Trading at -7.82% from the 50-Day Moving Average
After a stumble in the market that brought TMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.30% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMO starting from Pettiti Gianluca, who sale 400 shares at the price of $411.11 back on May 12 ’25. After this action, Pettiti Gianluca now owns 22,767 shares of Thermo Fisher Scientific Inc, valued at $164,444 using the latest closing price.
Pettiti Gianluca, the Officer of Thermo Fisher Scientific Inc, proposed sale 400 shares at $411.11 during a trade that took place back on May 12 ’25, which means that Pettiti Gianluca is holding shares at $164,444 based on the most recent closing price.
Stock Fundamentals for TMO
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.42 for the gross margin
The net margin for Thermo Fisher Scientific Inc stands at 0.15. The total capital return value is set at 0.09. Equity return is now at value 13.73, with 6.64 for asset returns.
Based on Thermo Fisher Scientific Inc (TMO), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.24. The debt to equity ratio resting at 0.69. The interest coverage ratio of the stock is 5.51.
Currently, EBITDA for the company is 11.8 billion with net debt to EBITDA at 2.84. When we switch over and look at the enterprise to sales, we see a ratio of 4.22. The receivables turnover for the company is 5.07for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
In a nutshell, Thermo Fisher Scientific Inc (TMO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
